Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Clinical data: Phase 1 trials of CJC-1295 showed significant increases in GH and IGF-1 levels in healthy adults Ipamorelin studied for postoperative ileus and GH modulation Evidence level: Moderate human data (mainly early-phase trials) + strong mechanistic and preclinical support TECHNICAL SPECIFICATIONS CJC-1295: Modified GHRH analog (with or without DAC) Ipamorelin: Pentapeptide ghrelin mimetic Common blend ratio: 1:1 (varies by formulation) Presentation: typically 5mg/5mg or 10mg total per vial Administration: Subcutaneous injection Targets: Pituitary gland (GH release) Liver (IGF-1 production) Key feature: Pulsatile GH stimulation without major endocrine suppression REGULATORY STATUS FDA Status: Not approved for general medical use
3) Promotion of glutaminase 2 (GLS2) expression: GLS2 expression is induced in a p53-dependent manner in response to DNA damage or oxidative stress, and p53 is associated with the GLS2 promoter
3, considerable edema
All weight loss medication decisions should be made in consultation with a licensed healthcare professional who can evaluate medical history, potential risks, contraindications, and overall suitability
If you have any concerns, contact us at [email protected]
The effort to create more entry points is an important part of the larger conversation about prevention and education
US$ 22.93
US$ 26.65
US$ 27.06
US$ 29.10
